<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053391</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258491</org_study_id>
    <secondary_id>ERLANGEN-1490</secondary_id>
    <secondary_id>EU-20232</secondary_id>
    <nct_id>NCT00053391</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make&#xD;
      the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients&#xD;
      who have stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of vaccination with autologous dendritic cells pulsed with tumor&#xD;
           and influenza antigen peptides treated with vs without ex vivo CD40-ligand, in terms of&#xD;
           tumor-specific T-cell response, in patients with HLA-A1 and/or HLA-A2.1 positive stage&#xD;
           III or IV melanoma.&#xD;
&#xD;
        -  Determine the safety and tolerability of these vaccinations in these patients.&#xD;
&#xD;
        -  Determine tumor response and recurrence rates in patients treated with these&#xD;
           vaccinations.&#xD;
&#xD;
      OUTLINE: This is an open-label non-randomized study.&#xD;
&#xD;
        -  Phase I: Patients undergo leukapheresis for collection of peripheral blood mononuclear&#xD;
           cells (PBMC). PBMC are cultured with sargramostim (GM-CSF) and interleukin-4 to generate&#xD;
           dendritic cells (DCs) on day -9. DCs are pulsed separately with HLA-A1 and&#xD;
           HLA-A2.1-restricted flu matrix peptides derived from melanoma-associated tumor antigens&#xD;
           (MAGE-10.A2, Melan-A, MAGE-3, NY-ESO-1, gp100 antigen, and tyrosinase peptide). Half of&#xD;
           the DCs are treated ex vivo with CD40-ligand. Patients receive the peptide-pulsed DC&#xD;
           vaccinations subcutaneously (SC) on days 1, 14, 42, and 70 in the absence of disease&#xD;
           progression.&#xD;
&#xD;
      Patients who show tumor response (at least stable disease) at day 98 progress to phase II of&#xD;
      the study.&#xD;
&#xD;
        -  Phase II: Patients undergo leukapheresis as in phase I on days 102, 352, and 688.&#xD;
           Patients receive up to 6 additional booster vaccinations SC as in phase I on days 126,&#xD;
           184, 268, 356, 520, and 692.&#xD;
&#xD;
      Patients are followed for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-30 patients will be accrued for this study within 6-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the efficacy of vaccination with vs without ex vivo CD40-ligand in terms of tumor-specific T-cell response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rates</measure>
  </secondary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant CD40-ligand</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage III or IV cutaneous malignant melanoma&#xD;
&#xD;
          -  HLA-A1 and/or HLA-A2 expression by serologic HLA typing&#xD;
&#xD;
               -  HLA-A2.1 subtype must be confirmed by polymerase chain reaction on genomic DNA&#xD;
                  obtained from peripheral blood mononuclear cells&#xD;
&#xD;
          -  No active CNS metastases by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 2,500/mm^3&#xD;
&#xD;
          -  Neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 700/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant respiratory disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
               -  No evidence of HIV-1, HIV-2, or human T-cell lymphotropic virus-1&#xD;
&#xD;
          -  No active autoimmune disease including (but not limited to):&#xD;
&#xD;
               -  Lupus erythematosus&#xD;
&#xD;
               -  Autoimmune thyroiditis or uveitis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Stable medical condition&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 1 month&#xD;
             after study participation&#xD;
&#xD;
          -  No organic brain syndrome or psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
          -  No other concurrent serious illness that would preclude study treatment&#xD;
&#xD;
          -  No contraindication to leukapheresis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  Concurrent surgery on selected metastases (e.g., because of pain or local&#xD;
             complications such as compression) allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler</last_name>
    <role>Study Chair</role>
    <affiliation>Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. univ. Beatrice Schuler-Thurner</investigator_full_name>
    <investigator_title>Prinicipal Investigator Prof. Dr. Schuler Gerold</investigator_title>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

